D&D Pharmatech tumbles 18% after Pfizer halts ORALINK candidate [K-bio pulse]

[Kim Jin Soo, Edaily Repoeter] D&D Pharmatech shares dropped sharply after it was confirmed that development had been halted on an obesity drug candidate built with the company's technology. Coming on the heels of questions about Peptron's technology evaluation agreement with Eli Lilly and Co., the news has shaken expectations for obesity treatments based on Korean biotech platforms.Dongwoon Anatech shares rose on news that the company had filed a clinical trial application for its saliva-based glucose meter and would soon release trial results.D&D Pharmatech Stock Trend. (KG Zeroin)D&D Pharmatech falls 18%D&D Pharmatech closed at 53,100 won on Aug. 5, down 18.06% from the previous session, according to MP Doctor, the KG Zeroin platform formerly known as Marketpoint. The decline is attributed to news that Metsera's obesity pipeline had been cut back.Pfizer Inc. said Aug. 4 in its second-quarter earnings materials that it had discontinued development of MET-224o, a candidate built on D&D Pharmatech's ORALINK oral peptide platform, according to industry officials.D&D Pharmatech licensed six oral obesity drug candidates to Metsera in 2023 for $803.5 million, an...